Treats cardiac decompensation due to depressed contractility. ANDA 216131, held by Hainan Poly. Dobutamine Hydrochloride.
As of Nov 16, 2026, ANDA 216131 (Dobutamine Hydrochloride), held by Hainan Poly, was first approved by FDA on Dec 21, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dobutamine HydrochlorideEQ 12.5MG BASE/ML · injectable;injection | Dobutamine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters